FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133281678> ?p ?o ?g. }

• W2133281678 endingPage "322" @default.
• W2133281678 startingPage "317" @default.
• W2133281678 abstract "Helicobacter pylori treatment still remains a challenge for physicians, and no current first-line therapies are able to cure the infection in all treated patients. Two very large meta-analysis studies showed that standard 7—14 days triple therapies fail to eradicate H. pylori infection in up to 20—25% of patients [Fuccio et al. 2007; Zullo et al. 2007]. In addition, the efficacy of these regimens is even decreasing worldwide. Indeed, during the last few years, different studies have found that the success rate following such regimens is disappointingly low, with values less than 45—60% in some countries [Gumurdulu et al. 2004; Vakil et al. 2004]. This phenomenon most likely depends on an increased bacterial resistance to antibiotics, particularly against clari-thromycin — the key antibiotic in H. pylori treatment [Megraud 2004]. In detail, clarithromycin resistance reduces success rate of standard triple therapies to mean values as low as 18—44%. Consequently, several patients deserve two or more therapeutic attempts to cure H. pylori infection in clinical practice. Therefore, as well as first-line regimens, both second-line and ‘rescue’ therapies have been advised in the updated international guidelines for H. pylori management [Caselli et al. 2007; Malfertheiner et al. 2007]. However, to cure the infection following a failed initial triple therapy is particularly difficult and costly, due to the need for further therapies and diagnostic tests. In a recent study, the cumulative eradication rate was 89.6% by using three consecutive standard therapies in patients treated in clinical practice, being only 70.3%, 69.1% and 70% following first-, second-, and third-line regimens, respectively [Rokkas et al. 2009]. All these observations clearly suggest that more efficacious therapy regimens are required as an initial therapy for clinical practice, the best first-line treatment being still regarded as the best ‘rescue’ therapy [Huang and Hunt 1999].In 2000, we conceived a novel therapeutic approach to cure H. pylori infection, namely a 10-day sequential therapy, which achieved a very high eradication rate [Zullo et al. 2000]. The sequential therapy is a simple dual therapy including a proton pump inhibitor (PPI) plus amoxicillin 1 g (both twice daily) given for the first 5 days followed by a triple therapy including a PPI, clarithromycin 500 mg, and tinidazole (all twice daily) for the remaining 5 days [Zullo et al. 2007]. To date, the efficacy of such a therapy regimen has been investigated in several trials overall enrolling more than 2000 patients. Based on these results, sequential therapy is now recognized as first-line therapy in the current Italian guidelines [Caselli et al. 2007]." @default.
• W2133281678 created "2016-06-24" @default.
• W2133281678 creator A5010158984 @default.
• W2133281678 creator A5022747830 @default.
• W2133281678 creator A5045834931 @default.
• W2133281678 creator A5062032345 @default.
• W2133281678 creator A5083959418 @default.
• W2133281678 date "2009-09-28" @default.
• W2133281678 modified "2023-10-16" @default.
• W2133281678 title "Sequential therapy for <i>Helicobacter pylori</i> eradication: the time is now!" @default.
• W2133281678 cites W1487725968 @default.
• W2133281678 cites W1528697828 @default.
• W2133281678 cites W1966732342 @default.
• W2133281678 cites W1968875125 @default.
• W2133281678 cites W1972377088 @default.
• W2133281678 cites W1980350531 @default.
• W2133281678 cites W1985740337 @default.
• W2133281678 cites W1993329113 @default.
• W2133281678 cites W2002580298 @default.
• W2133281678 cites W2010433727 @default.
• W2133281678 cites W2013134902 @default.
• W2133281678 cites W2015607646 @default.
• W2133281678 cites W2017202244 @default.
• W2133281678 cites W2022095414 @default.
• W2133281678 cites W2027142192 @default.
• W2133281678 cites W2032792335 @default.
• W2133281678 cites W2040194368 @default.
• W2133281678 cites W2046112814 @default.
• W2133281678 cites W2047048118 @default.
• W2133281678 cites W2060752995 @default.
• W2133281678 cites W2070211481 @default.
• W2133281678 cites W2071687048 @default.
• W2133281678 cites W2071797781 @default.
• W2133281678 cites W2082580119 @default.
• W2133281678 cites W2086507424 @default.
• W2133281678 cites W2086771104 @default.
• W2133281678 cites W2090556308 @default.
• W2133281678 cites W2091189969 @default.
• W2133281678 cites W2092407108 @default.
• W2133281678 cites W2101730203 @default.
• W2133281678 cites W2107138460 @default.
• W2133281678 cites W2118529094 @default.
• W2133281678 cites W2135538994 @default.
• W2133281678 cites W2136210283 @default.
• W2133281678 cites W2147911026 @default.
• W2133281678 cites W2153418611 @default.
• W2133281678 cites W2154994164 @default.
• W2133281678 cites W2181628751 @default.
• W2133281678 cites W4254917048 @default.
• W2133281678 cites W4367590684 @default.
• W2133281678 cites W4385616346 @default.
• W2133281678 doi "https://doi.org/10.1177/1756283x09343326" @default.
• W2133281678 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3002562" @default.
• W2133281678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21180579" @default.
• W2133281678 hasPublicationYear "2009" @default.
• W2133281678 type Work @default.
• W2133281678 sameAs 2133281678 @default.
• W2133281678 citedByCount "47" @default.
• W2133281678 countsByYear W21332816782012 @default.
• W2133281678 countsByYear W21332816782013 @default.
• W2133281678 countsByYear W21332816782014 @default.
• W2133281678 countsByYear W21332816782015 @default.
• W2133281678 countsByYear W21332816782016 @default.
• W2133281678 countsByYear W21332816782017 @default.
• W2133281678 countsByYear W21332816782018 @default.
• W2133281678 countsByYear W21332816782019 @default.
• W2133281678 countsByYear W21332816782020 @default.
• W2133281678 countsByYear W21332816782022 @default.
• W2133281678 countsByYear W21332816782023 @default.
• W2133281678 crossrefType "journal-article" @default.
• W2133281678 hasAuthorship W2133281678A5010158984 @default.
• W2133281678 hasAuthorship W2133281678A5022747830 @default.
• W2133281678 hasAuthorship W2133281678A5045834931 @default.
• W2133281678 hasAuthorship W2133281678A5062032345 @default.
• W2133281678 hasAuthorship W2133281678A5083959418 @default.
• W2133281678 hasBestOaLocation W21332816781 @default.
• W2133281678 hasConcept C126322002 @default.
• W2133281678 hasConcept C203014093 @default.
• W2133281678 hasConcept C2776409635 @default.
• W2133281678 hasConcept C71924100 @default.
• W2133281678 hasConceptScore W2133281678C126322002 @default.
• W2133281678 hasConceptScore W2133281678C203014093 @default.
• W2133281678 hasConceptScore W2133281678C2776409635 @default.
• W2133281678 hasConceptScore W2133281678C71924100 @default.
• W2133281678 hasIssue "6" @default.
• W2133281678 hasLocation W21332816781 @default.
• W2133281678 hasLocation W21332816782 @default.
• W2133281678 hasLocation W21332816783 @default.
• W2133281678 hasLocation W21332816784 @default.
• W2133281678 hasLocation W21332816785 @default.
• W2133281678 hasOpenAccess W2133281678 @default.
• W2133281678 hasPrimaryLocation W21332816781 @default.
• W2133281678 hasRelatedWork W1963611085 @default.
• W2133281678 hasRelatedWork W1995515455 @default.
• W2133281678 hasRelatedWork W2007002791 @default.
• W2133281678 hasRelatedWork W2080531066 @default.
• W2133281678 hasRelatedWork W2748952813 @default.
• W2133281678 hasRelatedWork W2899084033 @default.

• next